Università degli Studi di Urbino Carlo Bo / Portale Web di Ateneo


Struttura
Dipartimento di Scienze Biomolecolari (DISB) Fano Via Arco d'Augusto, 2 0722 304976 luca.galluzzi@uniurb.it
Sito web

Orlandi, C.; Stefanetti, G.; Barocci, S.; Buffi, G.; Diotallevi, A.; Rocchi, E.; Ceccarelli, M.; Peluso, S.; Vandini, D.; Carlotti, E.; Magnani, M.; Galluzzi, L.; Casabianca, A. Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. Viruses 2023, 15, 1162

Buffi G, Diotallevi A, Ceccarelli M, Bruno F, Castelli G, Vitale F, Magnani M, Galluzzi L. The host micro-RNA cfa-miR-346 is induced in canine leishmaniasis. BMC Vet Res. 2022 Jun 27;18(1):247. doi: 10.1186/s12917-022-03359-5

Laura Di Patria, Giosuè Annibalini, Amelia Morrone, Lorenzo Ferri, Roberta Saltarelli, Luca Galluzzi, Aurora Diotallevi, Matteo Bocconcelli, Maria Alice Donati, Rita Barone, Renzo Guerrini, Jaak Jaeken, Vilberto Stocchi, and Elena Barbieri. Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation. Cell Mol Life Sci. 2022 Feb 24;79(3):150. doi: 10.1007/s00018-022-04180-x. 

Diotallevi A, Scalvini L, Buffi G, Pérez-Pertejo Y, De Santi M, Verboni M, Favi G, Magnani M, Lodola A, Lucarini S, Galluzzi L. Phenotype Screening of an Azole-bisindole Chemical Library Identifies URB1483 as a New Antileishmanial Agent Devoid of Toxicity on Human Cells. ACS Omega. 2021 Dec 15;6(51):35699-35710. doi: 10.1021/acsomega.1c05611

Diotallevi A, Buffi G, Corbelli G, Ceccarelli M, Ortalli M, Varani S, Magnani M, Galluzzi L. In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy. Microorganisms. 2021 May 26;9(6):1147. doi: 10.3390/microorganisms9061147. 

Crinelli R, Zara C, Galluzzi L, Buffi G, Ceccarini C, Smietana M, Mari M, Magnani M, Fraternale A. Activation of NRF2 and ATF4 Signaling by the Pro-Glutathione Molecule I-152, a Co-Drug of N-Acetyl-Cysteine and Cysteamine. Antioxidants (Basel). 2021 Jan 26;10(2):175. doi:10.3390/antiox10020175.

Ceccarelli M, Buffi G, Diotallevi A, Andreoni F, Bencardino D, Vitale F, Castelli G, Bruno F, Magnani M, Galluzzi L. Evaluation of a kDNA-Based qPCR Assay for the Detection and Quantification of Old World Leishmania
Species. Microorganisms. 2020 Dec 16;8(12):2006. doi:10.3390/microorganisms8122006.

Fraternale A, Zara C, Di Mambro T, Manuali E, Genovese DA, Galluzzi L, Diotallevi A, Pompa A, De Marchis F, Ambrogini P, Cesarini E, Luchetti F, Smietana M, Green K, Bartoccini F, Magnani M, Crinelli R. I-152, a supplier of N-acetyl-cysteine and cysteamine, inhibits immunoglobulin secretion and plasma cell maturation in LP-BM5 murine leukemia retrovirus-infected mice by affecting the unfolded protein response. Biochim Biophys Acta Mol Basis Dis. 2020 Dec 1;1866(12):165922. doi: 10.1016/j.bbadis.2020.165922.

Ceccarelli M, Diotallevi A, Buffi G, De Santi M, Fernández-Figueroa EA, Rangel-Escareño C, Muñoz-Montero SA, Becker I, Magnani M, Galluzzi L. Differentiation of Leishmania (L.) infantum, Leishmania (L.) amazonensis and Leishmania (L.) mexicana Using Sequential qPCR Assays and High-Resolution Melt Analysis. Microorganisms. 2020 May 29;8(6):818. doi:10.3390/microorganisms8060818.

Diotallevi A, Buffi G, Ceccarelli M, Neitzke-Abreu HC, Gnutzmann LV, da Costa Lima MS Jr, Di Domenico A, De Santi M, Magnani M, Galluzzi L. Real-time PCR to differentiate among Leishmania (Viannia) subgenus, Leishmania (Leishmania) infantum and Leishmania (Leishmania) amazonensis: Application on Brazilian clinical samples. Acta Trop. 2020 Jan;201:105178. doi:10.1016/j.actatropica.2019.105178.

Prodotti della Ricerca di Luca Galluzzi.

vedi

A.A.
A.Y.
Insegnamento
Course
2024/2025 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2024/2025 MOLECULAR DIAGNOSTICS AND BIOMARKERS (MOD.1: MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASES)
MOLECULAR DIAGNOSTICS AND BIOMARKERS (MOD.1: MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASES)
2024/2025 NOVEL ANTIMICROBIAL STRATEGIES (MOD.4: DRUG DISCOVERY FOR LEISHMANIASIS)
NOVEL ANTIMICROBIAL STRATEGIES (MOD.4: DRUG DISCOVERY FOR LEISHMANIASIS)
2024/2025 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
Course partially taught in a foreign language
2024/2025 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
mutuato
Course partially taught in a foreign language
2023/2024 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2023/2024 Mod.1: Molecular diagnostics for infectious diseases
Mod.1: Molecular diagnostics for infectious diseases
Course entirely taught in a foreign language
2023/2024 Novel antimicrobial strategies - Mod. 4
Novel antimicrobial strategies - Mod. 4
Course entirely taught in a foreign language
2023/2024 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
Course partially taught in a foreign language
2023/2024 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
mutuato
Course partially taught in a foreign language
2022/2023 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2022/2023 MOLECULAR DIAGNOSTICS
MOLECULAR DIAGNOSTICS
Course entirely taught in a foreign language
2022/2023 NOVEL ANTIMICROBIAL STRATEGIES MOD.3
NOVEL ANTIMICROBIAL STRATEGIES MOD.3
Course entirely taught in a foreign language
2022/2023 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
Course partially taught in a foreign language
2022/2023 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
mutuato
Course partially taught in a foreign language
2021/2022 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2021/2022 MOLECULAR DIAGNOSTICS
MOLECULAR DIAGNOSTICS
Course entirely taught in a foreign language
2021/2022 NOVEL ANTIMICROBIAL STRATEGIES MOD. 3
NOVEL ANTIMICROBIAL STRATEGIES MOD. 3
Course entirely taught in a foreign language
2021/2022 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
Course partially taught in a foreign language
2021/2022 TECNOLOGIE E MODELLI DI STUDIO PER LA DIAGNOSTICA E LA TERAPIA
TECHNOLOGIES AND STUDY MODELS FOR DIAGNOSTIC AND THERAPY
mutuato
Course partially taught in a foreign language
2020/2021 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2020/2021 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
Course partially taught in a foreign language
2020/2021 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
mutuato
Course partially taught in a foreign language
2019/2020 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2019/2020 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
Course partially taught in a foreign language
2019/2020 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
mutuato
Course partially taught in a foreign language
2018/2019 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2018/2019 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
Course partially taught in a foreign language
2018/2019 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
mutuato
Course partially taught in a foreign language
2017/2018 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course partially taught in a foreign language
2017/2018 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
Course partially taught in a foreign language
2017/2018 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
mutuato
2016/2017 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
Course with optional materials in a foreign language
2016/2017 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
Course with optional materials in a foreign language
2016/2017 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
mutuato
Course with optional materials in a foreign language
2015/2016 BIOTECNOLOGIE DIAGNOSTICHE E TERAPEUTICHE
DIAGNOSTIC AND THERAPEUTIC BIOTECHNOLOGIES
2015/2016 TECNOLOGIE BIOLOGICHE AVANZATE
ADVANCED BIOLOGICAL TECHNOLOGIES
2014/2015 Biotecnologie diagnostiche e terapeutiche
2014/2015 Tecnologie biologiche avanzate
2013/2014 Biotecnologie diagnostiche e terapeutiche
2013/2014 Tecnologie biologiche avanzate
2012/2013 Tecnologie biologiche avanzate
2011/2012 Tecnologie biologiche avanzate
2010/2011 Biotecnologie molecolari e ricombinanti
2010/2011 Laboratorio di diagnostica immunologica e molecolare (modulo: Laboratorio di diagnostica molecolare)
2009/2010 Biotecnologie molecolari e ricombinanti
2009/2010 Modelli cellulari e animali per la ricerca sperimentale
2008/2009 Biotecnologie molecolari e ricombinanti
2007/2008 Biotecnologie molecolari e ricombinanti
2006/2007 Biotecnologie molecolari e ricombinanti
Giorno Orario Attività Aula

Il tuo feedback è importante

Raccontaci la tua esperienza e aiutaci a migliorare questa pagina.

Il tuo 5x1000 per sostenere le attività di ricerca

L'Università di Urbino destina tutte le risorse che deriveranno da questa iniziativa alla ricerca scientifica ed al sostegno di giovani ricercatori.

15 22

Se sei vittima di violenza o stalking chiama il 1522, scarica l'app o chatta su www.1522.eu

Il numero, gratuito è attivo 24 h su 24, accoglie con operatrici specializzate le richieste di aiuto e sostegno delle vittime di violenza e stalking.

Posta elettronica certificata

amministrazione@uniurb.legalmail.it

Social

Università degli Studi di Urbino Carlo Bo
Via Aurelio Saffi, 2 – 61029 Urbino PU – IT
Partita IVA 00448830414 – Codice Fiscale 82002850418
2024 © Tutti i diritti sono riservati

Top